Q-omics provides the consensus-scored CLCA3P profile across patient tissues and cancer cell-line models. CLCA3P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLCA3P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CLCA3P RNA expression shows 11,034 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CLCA3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLCA3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLCA3P survival associations across molecular data types. CLCA3P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLCA3P RNA expression–survival associations across cancer types. High CLCA3P expression shows unfavorable associations in KIRC, KICH, LGG, GBM and ACC, but favorable associations in MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLCA3P RNA expression.
This table summarizes CLCA3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLCA3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLCA3P shows lower tumor expression in KIRC, KICH and HNSC and higher tumor expression in LUAD, LUSC and UCEC. The KIRC box plot shows higher CLCA3P RNA expression in normal versus tumor tissue (log2 FC = −0.153, t-test p < 0.001).
This table shows molecular features associated with CLCA3P in patient tissues and cancer cell lines. In patient samples, CLCA3P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLCA3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
